These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 18500265

  • 1. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.
    Têtu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D.
    Mod Pathol; 2008 Aug; 21(8):1002-10. PubMed ID: 18500265
    [Abstract] [Full Text] [Related]

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.
    J Exp Clin Cancer Res; 2017 May 08; 36(1):63. PubMed ID: 28482906
    [Abstract] [Full Text] [Related]

  • 3. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
    Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A.
    BMC Cancer; 2006 Apr 11; 6():90. PubMed ID: 16606472
    [Abstract] [Full Text] [Related]

  • 4. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival.
    Choi CH, Choi JJ, Park YA, Lee YY, Song SY, Sung CO, Song T, Kim MK, Kim TJ, Lee JW, Kim HJ, Bae DS, Kim BG.
    Br J Cancer; 2012 Jun 26; 107(1):91-9. PubMed ID: 22644307
    [Abstract] [Full Text] [Related]

  • 5. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL, Kim J, Kwon MJ, Choi JS, Kim TJ, Bae DS, Koh SS, In YH, Park YW, Kim SH, Ahn G, Shin YK.
    Histol Histopathol; 2007 Nov 26; 22(11):1185-95. PubMed ID: 17647191
    [Abstract] [Full Text] [Related]

  • 6. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK.
    Oncotarget; 2017 Mar 14; 8(11):17819-17832. PubMed ID: 28147318
    [Abstract] [Full Text] [Related]

  • 7. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
    Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B.
    Gynecol Oncol; 2015 Oct 14; 139(1):30-9. PubMed ID: 26232338
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
    Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, Hwang YY, An HJ.
    Cancer Sci; 2010 Sep 14; 101(9):1977-83. PubMed ID: 20624166
    [Abstract] [Full Text] [Related]

  • 9. Poor survival with wild-type TP53 ovarian cancer?
    Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM.
    Gynecol Oncol; 2013 Sep 14; 130(3):565-9. PubMed ID: 23800698
    [Abstract] [Full Text] [Related]

  • 10. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B.
    Hum Pathol; 2012 Apr 14; 43(4):496-505. PubMed ID: 21855111
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
    Choi CH, Sung CO, Kim HJ, Lee YY, Song SY, Song T, Kim J, Kim TJ, Lee JW, Bae DS, Kim BG.
    Hum Pathol; 2013 Jun 14; 44(6):1017-23. PubMed ID: 23290009
    [Abstract] [Full Text] [Related]

  • 12. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.
    Br J Cancer; 2015 Mar 31; 112(7):1215-22. PubMed ID: 25826225
    [Abstract] [Full Text] [Related]

  • 13. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U, Denkert C, Braicu I, Sehouli J, Dietel M, Loibl S, Darb-Esfahani S.
    Virchows Arch; 2017 Feb 31; 470(2):143-151. PubMed ID: 27913862
    [Abstract] [Full Text] [Related]

  • 14. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.
    Espinosa I, Catasus L, Canet B, D'Angelo E, Muñoz J, Prat J.
    Mod Pathol; 2011 Jun 31; 24(6):846-54. PubMed ID: 21317880
    [Abstract] [Full Text] [Related]

  • 15. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ.
    J Gynecol Oncol; 2016 Jan 31; 27(1):e7. PubMed ID: 26463438
    [Abstract] [Full Text] [Related]

  • 16. Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma.
    Li C, Li Y, Wang X, Wang Z, Cai J, Wang L, Zhao Y, Song H, Meng X, Ning X, Xu C, Lin M, Li L, Geng J.
    Histopathology; 2012 May 31; 60(6):953-63. PubMed ID: 22372608
    [Abstract] [Full Text] [Related]

  • 17. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
    Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B.
    Hum Pathol; 2012 Nov 31; 43(11):2062-9. PubMed ID: 22647351
    [Abstract] [Full Text] [Related]

  • 18. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
    Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG.
    Hum Pathol; 2013 Nov 31; 44(11):2449-60. PubMed ID: 24011953
    [Abstract] [Full Text] [Related]

  • 19. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
    Kim YS, Hwan JD, Bae S, Bae DH, Shick WA.
    BMC Cancer; 2010 Oct 22; 10():576. PubMed ID: 20969748
    [Abstract] [Full Text] [Related]

  • 20. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
    Abdelrahman AE, Fathy A, Elsebai EA, Nawar N, Etman WM.
    Ann Diagn Pathol; 2018 Aug 22; 35():27-37. PubMed ID: 30072015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.